Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Sdiptech AB (publ) in connection with its listing on Nasdaq Stockholm
Mandate

Vinge has advised Sdiptech AB (publ) in connection with its listing on Nasdaq Stockholm

June 11, 2021 Capital Markets and Public M&A Corporate Tax M&A

Vinge has advised Sdiptech AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm’s main market. The prospectus was published on 8 June 2021 and the trading on Nasdaq Stockholm commenced on 11 June 2021.

Sdiptech is a technology group that acquires and develops market-leading niche operations that contribute to creating more sustainable, efficient and safe societies. Sdiptech has approximately SEK 2,000 million in sales and is based in Stockholm.

Vinge’s team has primarily consisted of Dain Hård Nevonen, William Kåge, Anders Sundin Lundberg and Benjamin Vafaeian (Capital Markets and Public M&A), Jesper Lindvall and Eléonore Friberg (M&A) and Victor Ericsson and Emelie Svanberg (Corporate Tax).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025